AD-A111 662 NAVAL AIR DEVELOPMENT CENTER WARMINSTER PA AIRCRAFT --ETC F/G 6/1
STUDIES ON THE MECHANISM OF ACTION OF THE IN VITRO PGB SUB X EF--ETC(U)
NOV 81 H W SHMUKLER, M G ZAWRYT, E SOFFER
UNCLASSIFIED NADC-81245-60 NL

END
DATE FILMED
3 82
DTIC


1.0
1.1
1.25
1.4
1.6
1.8
2.0
2.2
2.5
2.8
3.2
3.6
4.0
4.5
5.0
MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS 1963 A

REPORT NO. NADC-81245-60

12

STUDIES ON THE MECHANISM OF ACTION OF THE IN VITRO PGB_x EFFECT

V. THE EFFECT OF HYPOXIA

H. W. Shmukler, Ph.D.
Biochemistry Research Team
Aircraft and Crew Systems Technology Directorate
Naval Air Development Center
Warminster, Pennsylvania 18974

M. G. Zawryt, B.A.
E. Soffer, B.A.
Hahnemann Medical College and Hospital
Philadelphia, Pennsylvania 19102

19 November 1981

Phase Report
Airtask No. F58527803
Work Unit No. EH810

APPROVED FOR PUBLIC RELEASE; DISTRIBUTION UNLIMITED

Prepared for
Office of Naval Research
Department of the Navy
Arlington, Virginia 22217

NOTICES

REPORT NUMBERING SYSTEM – The numbering of technical project reports issued by the Naval Air Development Center is arranged for specific identification purposes. Each number consists of the Center acronym, the calendar year in which the number was assigned, the sequence number of the report within the specific calendar year, and the official 2-digit correspondence code of the Command Office or the Functional Directorate responsible for the report. For example: Report No. NADC-78015-20 indicates the fifteenth Center report for the year 1978, and prepared by the Systems Directorate. The numerical codes are as follows:

CODE	OFFICE OR DIRECTORATE
00	Commander, Naval Air Development Center
01	Technical Director, Naval Air Development Center
02	Comptroller
10	Directorate Command Projects
20	Systems Directorate
30	Sensors & Avionics Technology Directorate
40	Communication & Navigation Technology Directorate
50	Software Computer Directorate
60	Aircraft & Crew Systems Technology Directorate
70	Planning Assessment Resources
80	Engineering Support Group

PRODUCT ENDORSEMENT – The discussion or instructions concerning commercial products herein do not constitute an endorsement by the Government nor do they convey or imply the license or right to use such products.

APPROVED BY: J. W. Woods DATE: 2/2/82

J. W. WOODS
CDR USN

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER NADC-81245-60	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) Studies on the Mechanism of Action of the in vitro PGB_x Effect. V. The Effect of Hypoxia.		5. TYPE OF REPORT & PERIOD COVERED Phase Report 6. PERFORMING ORG. REPORT NUMBER
7. AUTHOR(s) H. W. Shmukler, M. G. Zawryt and E. Soffer		8. CONTRACT OR GRANT NUMBER(s) N00014-81-WR10070
9. PERFORMING ORGANIZATION NAME AND ADDRESS Naval Air Development Center Aircraft & Crew Systems Technology Directorate Warminster, Pennsylvania 18974		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS Airtask: F58527803 Work Unit No.: EH810
11. CONTROLLING OFFICE NAME AND ADDRESS Office of Naval Research Department of the Navy Arlington, Virginia 22217		12. REPORT DATE 19 November 1981 13. NUMBER OF PAGES
14. MONITORING AGENCY NAME & ADDRESS(if different from Controlling Office)		15. SECURITY CLASS. (of this report) UNCLASSIFIED 15a. DECLASSIFICATION/DOWNGRADING SCHEDULE

16. DISTRIBUTION STATEMENT (of this Report)

APPROVED FOR PUBLIC RELEASE; DISTRIBUTION UNLIMITED

17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)

18. SUPPLEMENTARY NOTES

19. KEY WORDS (Continue on reverse side if necessary and identify by block number)

Prostaglandins, Oxidative phosphorylation, Rat Liver Mitochondria (RLM), Anaerobiosis

20. ABSTRACT (Continue on reverse side if necessary and identify by block number)

Normal RLM exposed to hypotonic media at 27° rapidly lose their ability to carry out oxidative phosphorylation. However when the hypotonic exposure is carried out in the absence of oxygen, these RLM will maintain a high degree of oxidative phosphorylation. PGB_x added to these RLM has no effect on the oxidative phosphorylation reactions.

DD FORM 1 JAN 73 1473 EDITION OF 1 NOV 65 IS OBSOLETE
S/N 0102-LF-014-6601

UNCLASSIFIED
SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

TABLE OF CONTENTS

INTRODUCTION

The therapeutic use of PGB_X (1, 2, 3, 4) in the treatment of human ischemic pathologies was suggested by successful animal experiments in a number of laboratories (5, 6, 7, 8, 9, 10, 11, 12). Before human trials may be attempted, it is necessary to first know the mechanism of the in vivo action of PGB_X. Towards this end studies have been underway in this laboratory to elucidate the in vitro mechanism of the PGB_X effect on phosphorylation activity of degraded RLM, in the hope that this would then lead to an understanding of the in vivo mechanisms of action.

In earlier reports Polis et al (3) and Angelakos et al (7, 8) indicated that the PGB_X effect can only be demonstrated with degraded RLM. In preceding reports of this series, we pointed out that the PGB_X effect could only be demonstrated with RLM exposed to modified State 4 Respiratory Conditions (13) i.e. nucleotides omitted. It was further reported that the PGB_X effect was dependent upon the composition of the State 4 Respiratory Conditions (14) and on the order of addition of PGB_X and RLM to the test system (15).

In this report we show that oxygen is an absolute requirement for the PGB_X effect. This oxygen requirement is over and above that required for oxidative phosphorylation reaction of RLM.

EXPERIMENTAL

Methods and Materials

PGB_X (Type II) (16) was synthesized as described previously (2, 3, 4) and assayed for its effect on the oxidative phosphorylation ability of degraded RLM by the method of Polis et al (2, 3, 4). The dissolved oxygen concentration was determined with a YSI Biological Oxygen Monitor (Yellow Springs Instrument Co. Inc., Yellow Springs, Ohio).

Note: Abbreviations used in this report are: RLM, rat liver mitochondria; mS4RC, modified State 4 Respiratory Conditions; Pi, inorganic phosphate.

RESULTS

Stability of RLM exposed to anaerobic conditions

In the normal PGB_x in vitro assay system, RLM are incubated in the mS4RC mixture equilibrated with air during both the degradation stage and the phosphorylation stage. In this study we carried out the degradation of RLM in a deoxygenated medium, and since oxygen is an absolute requirement for oxidative phosphorylation, it was necessary then to re-equilibrate the deoxygenated medium with air prior to the addition of the reactants of the 2nd stage of the PGB_x assay. The experimental protocol is described in the following text.

TABLE I

The Composition of the Medium for the Demonstration of the PGB_x Effect on Mitochondrial Oxidative Phosphorylation

Order of Addition	Mitochondrial Degrading Medium	Reaction Mixture
Water	1.55 ml	1.55 ml
Phosphate Buffer pH 7.35	4.98 mM	4.55 mM
α-Ketoglutarate pH 7.35	14.93 mM	13.64 mM
$MgSO_4$	4.98 mM	4.55 mM
Aged Mitochondria	1.99 mg/ml	1.82 mg/ml
Sucrose*	5.97 mM	5.45 mM
EDTA*	0.010 mM	0.0009 mM
AMP	-----	2.27 mM
ADP	-----	2.27 mM
KCl	-----	45.45 mM
Bovine Serum Albumin	-----	0.68 mg/ml

Total Volume: 2.20 ml
Temperature: 28°
Degradation Time: 5-20 minutes
Reaction Time: 20 minutes

*Added with mitochondria

Table I lists the reactants of Stage 1 and Stage 2 of the in vitro PGB_x assay system as well as the assay conditions. In this study, because of the size of the chambers of the Biological Monitor, the total volume was doubled. The degradation mixture (3.94 ml) was added to the Biological Oxygen Monitor Chamber and equilibrated to constant temperature (27°). The oxygen sensor was then inserted in the chamber and lowered to about 1/2 cm above the liquid. A stream of nitrogen was directed just above the stirred liquid by means of a narrow gauge hypodermic needle fitted through the access slot of the sensor. At periodic intervals the gas flow was stopped, the sensor lowered below the liquid level to expell all gas bubbles and the dissolved oxygen determined. If the dissolved oxygen content was not zero, the sensor was raised above the liquid and the flow of nitrogen continued. This process was repeated until the mixture was completely deoxygenated. In preliminary tests the time required to deoxygenate the degradation medium was 1.5 minutes, however in this study a deoxygenation time of three minutes was used routinely to assure complete deoxygenation without the need to analyze the oxygen content for each test. The purpose of this was to maintain a constant volume of the degradation mixture since each time the sensor is lowered into the liquid some of the liquid is expelled through the access slot. RLM (8.0 mg) were added to the deoxygenated medium, the flow of nitrogen started and the solution stirred. In this way the RLM were exposed to a hypotonic medium under anaerobic conditions. At the end of the exposure time, the sensor was removed and the gases above the liquid replaced with air by applying a vacuum in the chamber. In preliminary tests it was found that the solution could be completely reoxygenated within ten seconds. Routinely 15 seconds reoxygenation time was used and the reagents of Stage 2 in vitro PGB_x effect were then added and the reaction continued for 20 minutes. The Pi esterified was then measured as described previously (2, 3). With this short reoxygenation time no adverse effect on RLM phosphorylation activity was measurable.

Figure 1 shows the effect of exposing RLM to mS4RC under aerobic and anaerobic conditions. The results are plotted as the residual phosphorylation ability of RLM as a function of time of exposure to the hypotonic media. Curve X——X is the normal PGB assay curve, i.e. aerobic, while curve o —— o the assay curve obtained under anaerobic conditions. The phosphorylating ability of RLM exposed to aerobic conditions falls rapidly with time, and by eight minutes is completely void of all phosphorylating activity. This rate of loss of activity is a function of the age of RLM. Freshly isolated RLM still are capable of phosphorylation activity even after 20-30 minutes exposure. However the time required to reduce the phosphorylation activity is lessened as the RLM age. In contrast to the normal response, the phosphorylation activity of RLM exposed to hypotonic medium in the absence of oxygen was maintained at a consistently high level, even after 20 minutes exposure.

The effect of PGB_x on the phosphorylation activity of RLM exposed to hypotonic media under anaerobic and aerobic conditions were tested by carrying out the assays with varying amounts of PGB_x using a constant exposure time of five minutes. The results are plotted in Figure 2. As expected, the aerobic reaction gave the typical PGB_x-Type II biphasic response in that a maximum phosphorylation activity was found when RLM were treated with 2.27 to 9.09 µg PGB_x per ml of reaction (1.25 to 5.0 µg PGB_x/mg RLM). In contrast only minor changes were observed in the phosphorylation ability of RLM degraded under anaerobic conditions. With only a five minute exposure time, only a small amount of phosphorylation inhibition was observed (see 0 PGB_x concentration). At higher concentrations of PGB_x there was an improvement in phosphorylation activity. Most interesting was the finding that the highest concentration of PGB_x (20 µg/mg RLM), completely reduced the phosphorylation ability of aerobically degraded RLM to zero. Under anaerobic conditions similarly treated RLM functioned with a high degree of phosphorylation ability.

DISCUSSION

The *in vitro* PGB_x effect on rat liver mitochondrial oxidative phosphorylation was proposed by Polis *et al* (2, 3) to be an enhancement of the decreased phosphorylation ability of damaged RLM resulting from exposure to hypotonic media at 27°. This PGB_x effect was recently shown by Shmukler *et al* (14, 15) to take place only when RLM were exposed to degradative conditions in the presence of PGB_x. From these results it was concluded that PGB_x functions to stabilize RLM during exposure to degradative conditions. The results of the study reported here, support this mechanism. When RLM are exposed to hypotonic shock under anaerobic conditions, they still maintain a high degree of oxidative phosphorylation, suggesting that these RLM are not degraded. This conclusion is supported by the finding that when these RLM are pretreated with PGB_x according to the *in vitro* PGB_x assay system, no effect on phosphorylation was observed. This is similar to that observed when undegraded isolated RLM are treated with PGB_x.



Figure 1. The Effect of Oxygen on the PGB_x Maintenance of Phosphorylation Activity of RLM Exposed to Hypotonic Media. Curve + —— + is the phosphorylation activity of RLM exposed to hypotonic media under aerobic conditions, as a function of exposure time. This is the normal conditions for measuring the PGB_x effect and the analytical details were reported previously (2, 3, 4) and under "Methods" of this report. Curve o —— o is the phosphorylation activity of RLM exposed to hypotonic media under anaerobic conditions.



Figure 2. The Effect of Oxygen on the phosphorylation ability of PGB_x-treated RLM Exposed to Hypotonic Media. Curve • —— • was measured under aerobic conditions; curve o —— o was measured under anaerobic conditions. The analytical details were described previously (2, 3, 4) and under "Methods" of this report.

REFERENCES

1. Polis, B. D., A. M. Grandizio and E. Polis: Some in vitro and in vivo Effects of a New Prostaglandin Derivative. Neurohumoral and Metabolic Aspects of Injury. Adv. in Exper. Med. and Biol., Plenum Press, New York 33:213-220 (1973).

2. Polis, B. D., S. F. Kwong, E. Polis and G. Nelson: Studies on PGB_X: A Polymeric Derivative of Prostaglandin B_1: I - Synthesis and Purification of PGB_X. Report No. NADC-78235-60 (1978).

3. Polis, B. D., E. Polis and S. F. Kwong: Protection and Reactivation of Oxidative Phosphorylation in Mitochondria by a Stable Free-Radical Prostaglandin Polymer (PGB_X). Proc. Natl. Acd. Sci., 76:1598-1602 (1979).

4. Polis, B. D., S. F. Kwong, E. Polis, G. Nelson, and H. W. Shmukler. Studies on PGB_X, a polymeric derivative of prostaglandin B_1: I - Synthesis and purification of PGB_X. Physiol. Chem. Phys., 11, 109 (1979).

5. Angelakos, E. T., B. D. Polis and R. L. Riley: Recovery After Coronary Ligation and Fibrillation in Primates Treated with a Prostaglandin Derivative. 47th Scientific Sessions American Heart Association, Abstracts, Dallas, Texas (1974).

6. Angelakos, E. T., B. D. Polis and R. L. Riley: Protection by a Prostaglandin Derivative from Mortality after Coronary Ligation from Ventricular Fibrillation in Primates. 6th International Congress of Pharmacology Abstracts, Helsinki, Finland (1975).

7. Angelakos, E. T., R. L. Riley and B. D. Polis: Recovery of Monkeys from Cardiogenic Shock After Myocardial Infarction with Ventricular Fibrillation. Effects of PGB_X. Report No. NADC-77308-60 (1977).

8. Angelakos, E. T., R. L. Riley and B. D. Polis. Recovery of Monkeys after Myocardial Infarction with Ventricular Fibrillation. Effects of PGB_X. Physiol. Chem. Phys., 12, 81 (1980).

9. Kolata, R. J.: The Effect of PGB_X on Neurological Recovery from Cerebral Ischemia in Rabbits. Masters Thesis, Univ. of Penna. Veterinary School (1977).

10. Kolata, R. J. and B. D. Polis: Facilitation of Recovery from Ischemic Brain Damage in Rabbits by Polymeric Prostaglandin PGB_X, a Mitochondrial Protective Agent. Physiol. Chem. and Physics 12, 551 (1980).

11. Yamazaki, H., M. M. Bodenheimer, V. S. Banka, J. Lewandowski and R. H. Helfant: The Effect of a New Prostaglandin (PGB_X) on Length-tension.

12. Moss, G., T. Magliochetti and R. Quarmby: Immediate Restoration of Central Nervous System Autonomic Cardio-pulmonary Control: Survival of "Lethal" Cerebral Hypoxia by Treatment with PGB_X. Surgical Forum, 21:513 (1978).

13. Chance, B. and G. R. Williams: Respiratory Enzymes in Oxidative Phosphorylation III. Steady State. J. Biol. Chem. 217, 409 (1955).

14. Shmukler, H. W., M. G. Zawryt and E. Soffer: Studies on the Mechanism of Action of the in vitro PGB_X Effect. I. Composition of Reaction Medium of PGB_X Effect. Report No. NADC-81223-60 (1981).

15. Shmukler, H. W., M. G. Zawryt and E. Soffer: Studies on the Mechanism of Action of the in vitro PGB_X Effect. IV. The Effect of Order of Addition of PGB_X to Assay System. Report No. NADC-81244-60 (1981).

16. Shmukler, H. W., S. F. Kwong, E. Soffer, M. G. Zawryt, W. Feely and E. Polis: Studies on PGB_X: Fractionation by a Combination of Dialysis and Molecular Exclusion Chromatography. Report No. NADC-80156-60 (1980).

DISTRIBUTION LIST

REPORT NO. NADC-81245-60
CONTRACT NO. N00014-81-WR10070

	No. of Copies
Director, Defense Technical Information Center, Building 5, Cameron Station, Alexandria, VA 22314	12
Commanding Officer, Naval Research Laboratory, Technical Information Division (Code 2627), Washington, DC 20375	6
Chief of Naval Research, Code 102IP (ONRL DOC), 800 N. Quincy Street, Arlington, VA 22217	6
Chief of Naval Research, Biophysics Program (Code 444), 800 N. Quincy Street, Arlington, VA 22217	3
Chief of Naval Research (Code 200), 800 N. Quincy Street, Arlington, VA 22217	1
Commanding Officer, Office of Naval Reserach, Eastern/Central Regional Office, Building 114, Section D, 666 Summer Street, Boston, MA 02210	2
Commanding Officer, Office of Naval Research, Branch Office, 536 S. Clark Street, Chicago, IL 60605	1
Commanding Officer, Office of Naval Research, Western Regional Office, 1030 E. Green Street, Pasadena, CA 91106	1
Commanding Officer, Naval Medical Research & Development Command, National Naval Medical Center, Bethesda, MD 20014	1
Chief, Bureau of Medicine & Surgery, Navy Department, Washington, DC 20372	1
Commanding Officer, Naval Medical Research Institute, Tech. Ref. Library, National Naval Medical Center, Bethesda, MD 20014	2
Commanding Officer, Naval Medical Research Unit No. 2, APO San Francisco 96528	1
Commanding Officer, U.S. Naval Medical Research Unit No. 3, FPO New York 09527	1
Commanding Officer, Submarine Medical Research Laboratory, Naval Submarine Base, New London, Groton, CT 06340	1
Commanding Officer, Naval Aerospace Medical Research Laboratory, Naval Air Station, Pensacola, FL 32508	1
Commanding Officer, Naval Aerospace Medical Institute, Naval Air Station, Pensacola, FL 32508	1
Commanding Officer, Naval Supply Center, Naval Biosciences Laboratory, Oakland, CA 94625	1
Commanding Officer, Army Research Office, P.O. Box 12211, Research Triangle Park, NC 27709	1
Commanding Officer, Air Force Office of Scientific Research, Directorate of Life Sciences, Bolling Air Force Base, Washington, DC 20332	1
Commanding Officer, Army Medical & Development Command, Forrestal Building, Washington, DC 20314	1
Commanding Officer, Department of the Army, U.S. Army Science & Technology Center, Far East, APO, San Francisco, CA 96328	1